Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines in oncology, autoimmune disease and inflammatory conditions. The NRIX news feed on Stock Titan aggregates company announcements, clinical updates and regulatory disclosures so readers can follow how its pipeline and collaborations evolve over time.
News about Nurix frequently centers on clinical trial results and milestones for its lead programs. Recent releases describe new and updated data from Phase 1a/1b studies of the BTK degrader bexobrutideg (NX-5948) in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, including objective response rates, durability of responses and safety findings. Additional updates cover translational and clinical data for NX-1607, an oral CBL-B inhibitor for solid tumors, highlighting immune activation, tumor microenvironment remodeling and disease control in heavily pretreated patients.
Investors and clinicians can also use the NRIX news page to track corporate and regulatory events such as the initiation of the pivotal DAYBreak CLL-201 Phase 2 study, plans for a confirmatory Phase 3 trial, expansion of bexobrutideg into autoimmune and inflammatory indications, and participation in major medical and investor conferences including the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer (SITC) and the J.P. Morgan Healthcare Conference.
Nurix’s news flow further includes announcements on strategic collaborations and governance, such as progress in partnered STAT6 and IRAK4 degrader programs with Sanofi and Gilead, and board appointments that add drug development and commercialization experience. Bookmark this page to access a consolidated view of NRIX press releases and related coverage as the company advances its targeted protein degradation pipeline.
Nurix Therapeutics (NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's president and CEO, Arthur T. Sands, M.D., Ph.D., will engage in a fireside chat on Tuesday, February 11, 2025, at 12:40 p.m. ET.
The company, which focuses on developing innovative treatments for cancer and inflammatory diseases, will make the event available through a live webcast. Interested parties can access the webcast through the Investors section of Nurix's website, and the recording will remain accessible for 30 days following the event.
Nurix Therapeutics (NRIX) reported significant progress in its fourth quarter and fiscal year 2024. The company achieved a 75.5% objective response rate in its Phase 1 study of NX-5948 for CLL/SLL patients. NX-5948 received both PRIME designation from European Medicines Agency and Fast Track designation from FDA.
Financial highlights include cash and marketable securities of $609.6 million. Revenue for FY2024 was $54.5 million, down from $77.0 million in FY2023. Net loss increased to $193.6 million ($2.88 per share) compared to $143.9 million ($2.65 per share) in FY2023.
The company appointed John Northcott as Chief Commercial Officer and plans to launch pivotal clinical trials for NX-5948 in 2025. Research and development expenses increased to $221.6 million in FY2024 from $189.1 million in FY2023.
Nurix Therapeutics (NRIX) has appointed John Northcott as Chief Commercial Officer. Northcott brings over 20 years of biopharmaceutical experience, notably in commercializing the BTK inhibitor ibrutinib. The appointment comes as Nurix prepares to launch its pivotal clinical program for NX-5948 in chronic lymphocytic leukemia and other potential B-cell malignancies.
Northcott's recent roles include serving as CCO at Arvinas (2022-2024), where he built commercial infrastructure for a novel breast cancer treatment, CCO at Nektar Therapeutics (2019-2022), and CCO at Pharmacyclics (2015-2019), where he led the successful commercialization of ibrutinib. His experience spans both pre-launch planning and on-market commercialization in hematology, oncology, and other therapeutic areas.
Nurix Therapeutics (NRIX) has outlined its key objectives for 2025, highlighting significant progress in clinical trials and business development. The company reported impressive clinical responses from its NX-5948 Phase 1a/1b trial, achieving a 75.5% objective response rate in chronic lymphocytic leukemia patients. NX-5948 received Fast Track Designation from the FDA and PRIME designation from the European Medicines Agency.
The company plans to initiate pivotal studies for NX-5948 in 2025 and expand its development in additional cancer indications and inflammatory diseases. Nurix maintains a strong financial position with an estimated $609.6 million in cash and investments at fiscal 2024 year-end, expected to fund operations into the first half of 2027.
Key developments include the advancement of partnered programs in inflammation and immunology, including degraders of IRAK4 and STAT6, and investment in their DEL-AI discovery engine for novel degrader-based treatments.
Nurix Therapeutics (NRIX), a clinical stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's president and CEO, Arthur T. Sands, M.D., Ph.D., will deliver a corporate update presentation on Monday, January 13, 2025, at 3:00 p.m. PT in San Francisco.
The presentation will be accessible through a live webcast, with a link available in the Investors section of the Nurix website. For those unable to attend live, the webcast recording will remain accessible for 30 days following the event.
Nurix Therapeutics (NRIX) has received FDA Fast Track designation for NX-5948, its selective BTK degrader, for treating relapsed/refractory Waldenstrom's macroglobulinemia patients who have undergone at least two prior therapies, including a BTK inhibitor. This designation follows positive Phase 1 clinical trial data and adds to the drug's existing Fast Track designation for CLL/SLL treatment received in January 2024. NX-5948 also received EMA PRIME designation in November 2024 for treating CLL/SLL. The company continues patient enrollment in the Phase 1b expansion cohort, with additional clinical data expected in 2025.
Nurix Therapeutics (NRIX) presented positive Phase 1a/1b clinical trial data for NX-5948 in treating chronic lymphocytic leukemia. The trial showed a 75.5% Objective Response Rate, increasing to 84.2% in patients with at least two disease assessments. The study included 60 heavily pretreated patients who received a median of four prior therapies.
The drug demonstrated effectiveness in patients with mutations associated with poor prognosis and BTK inhibitor resistance, including those with CNS involvement. NX-5948 showed a favorable safety profile across all doses tested, with common side effects including purpura/contusion, fatigue, and neutropenia. Responses were durable, with thirteen patients showing response beyond six months and five patients maintaining response past one year of treatment.
Nurix Therapeutics (NRIX) announced a webcast scheduled for December 9, 2024, at 8:15 p.m. PT to present new clinical data from its ongoing Phase 1a/1b trial of BTK degrader NX-5948. The presentation will feature Dr. Nirav N. Shah from the Medical College of Wisconsin, who will discuss trial results in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Company executives will outline the clinical development strategy for NX-5948 in both oncology and autoimmune indications, along with updates on other clinical stage programs.
Nurix Therapeutics (Nasdaq: NRIX), a clinical stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Arthur T. Sands, M.D., Ph.D., president and CEO, will deliver a corporate update on December 3, 2024, at 2:30 p.m. ET in New York City. The presentation will be available via live webcast through the company's website, with the recording accessible for 30 days following the event.
Nurix Therapeutics (NRIX) has received PRIME designation from the European Medicines Agency for NX-5948, its selective BTK degrader, for treating relapsed or refractory chronic lymphocytic leukemia patients who have previously received BTK and BCL-2 inhibitor therapy. The PRIME designation, which provides enhanced support for promising medicines addressing unmet medical needs, was granted based on encouraging safety and efficacy data from ongoing Phase 1 trials. NX-5948 has shown potential activity against mutations resistant to current BTK inhibitors, with pivotal trials planned for 2025.